Full text is available at the source.
Abstract
Incretin therapy may significantly promote weight reduction through appetite suppression and metabolic improvements.
- Glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists are central to obesity management.
- Liraglutide, semaglutide, and tirzepatide are associated with decreased caloric intake.
- Recent studies indicate that semaglutide and tirzepatide may achieve substantial weight loss beyond just lowering glucose levels.
- Challenges regarding long-term efficacy, tolerability, and accessibility of these therapies remain.
- Future efforts could focus on optimizing combination therapies and developing new incretin-based molecules with additional receptor activity.
Simplified